BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 10673996)

  • 1. Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome.
    Cattelan AM; Calabro ML; Aversa SM; Zanchetta M; Meneghetti F; De Rossi A; Chieco-Bianchi L
    Eur J Cancer; 1999 Dec; 35(13):1809-15. PubMed ID: 10673996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome.
    Cattelan AM; Calabrò ML; Gasperini P; Aversa SM; Zanchetta M; Meneghetti F; De Rossi A; Chieco-Bianchi L
    J Natl Cancer Inst Monogr; 2001; (28):44-9. PubMed ID: 11158206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma.
    Lebbé C; Blum L; Pellet C; Blanchard G; Vérola O; Morel P; Danne O; Calvo F
    AIDS; 1998 May; 12(7):F45-9. PubMed ID: 9619797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi's sarcoma.
    Tedeschi R; Enbom M; Bidoli E; Linde A; De Paoli P; Dillner J
    J Clin Microbiol; 2001 Dec; 39(12):4269-73. PubMed ID: 11724831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of highly active antiretroviral therapy on AIDS-associated Kaposi's sarcoma.
    Dupin N; Rubin De Cervens V; Gorin I; Calvez V; Pessis E; Grandadam M; Rabian C; Viard JP; Huraux JM; Escande JP
    Br J Dermatol; 1999 May; 140(5):875-81. PubMed ID: 10354025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.
    Bihl F; Mosam A; Henry LN; Chisholm JV; Dollard S; Gumbi P; Cassol E; Page T; Mueller N; Kiepiela P; Martin JN; Coovadia HM; Scadden DT; Brander C
    AIDS; 2007 Jun; 21(10):1245-52. PubMed ID: 17545700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of HIV-infected patients with Kaposi's sarcoma receiving nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy in Uganda.
    Asiimwe F; Moore D; Were W; Nakityo R; Campbell J; Barasa A; Mermin J; Kaharuza F
    HIV Med; 2012 Mar; 13(3):166-71. PubMed ID: 22112164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma.
    Bower M; Fox P; Fife K; Gill J; Nelson M; Gazzard B
    AIDS; 1999 Oct; 13(15):2105-11. PubMed ID: 10546864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term clinical outcome of AIDS-related Kaposi's sarcoma during highly active antiretroviral therapy.
    Cattelan AM; Calabrò ML; De Rossi A; Aversa SM; Barbierato M; Trevenzoli M; Gasperini P; Zanchetta M; Cadrobbi P; Monfardini S; Chieco-Bianchi L
    Int J Oncol; 2005 Sep; 27(3):779-85. PubMed ID: 16077928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l'immunodéficience humaine.
    Dupont C; Vasseur E; Beauchet A; Aegerter P; Berthé H; de Truchis P; Zucman D; Rouveix E; Saiag P
    AIDS; 2000 May; 14(8):987-93. PubMed ID: 10853980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma.
    Renwick N; Halaby T; Weverling GJ; Dukers NH; Simpson GR; Coutinho RA; Lange JM; Schulz TF; Goudsmit J
    AIDS; 1998 Dec; 12(18):2481-8. PubMed ID: 9875587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral therapy with protease inhibitors in human immunodeficiency virus type 1- and human herpesvirus 8-coinfected patients.
    De Milito A; Catucci M; Venturi G; Romano L; Incandela L; Valensin PE; Zazzi M
    J Med Virol; 1999 Feb; 57(2):140-4. PubMed ID: 9892398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seroreactivity to Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) latent nuclear antigen in AIDS-associated Kaposi's sarcoma patients depends on CD4+ T-cell count.
    de Souza VA; Pierrotti LC; Sumita LM; Freire WS; Segurado AA; Pannuti CS
    J Med Virol; 2007 Oct; 79(10):1562-8. PubMed ID: 17705173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-Infected patients receiving highly active antiretroviral therapy.
    Wilkinson J; Cope A; Gill J; Bourboulia D; Hayes P; Imami N; Kubo T; Marcelin A; Calvez V; Weiss R; Gazzard B; Boshoff C; Gotch F
    J Virol; 2002 Mar; 76(6):2634-40. PubMed ID: 11861829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy.
    Pellet C; Chevret S; Blum L; Gauvillé C; Hurault M; Blanchard G; Agbalika F; Lascoux C; Ponscarme D; Morel P; Calvo F; Lebbé C
    J Invest Dermatol; 2001 Oct; 117(4):858-63. PubMed ID: 11676823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma.
    Portsmouth S; Stebbing J; Gill J; Mandalia S; Bower M; Nelson M; Bower M; Gazzard B
    AIDS; 2003 Jul; 17(11):F17-22. PubMed ID: 12853764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kaposi sarcoma herpes virus antibody response and viremia following highly active antiretroviral therapy in the Swiss HIV Cohort study.
    Sullivan SG; Hirsch HH; Franceschi S; Steffen I; Amari EB; Mueller NJ; Magouras I; Biggar RJ; Rickenbach M; Clifford GM;
    AIDS; 2010 Sep; 24(14):2245-52. PubMed ID: 20543658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clearance of human herpesvirus type 8 viraemia in HIV-1-positive patients with Kaposi's sarcoma treated with liposomal doxorubicin. Caelyx/KS Spanish Study Group.
    Núñez M; Machuca A; Soriano V; Podzamczer D; González-Lahoz J
    AIDS; 2000 May; 14(8):913-9. PubMed ID: 10853972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HHV-8 DNA replication correlates with the clinical status in AIDS-related Kaposi's sarcoma.
    Broccolo F; Tassan Din C; Viganò MG; Rutigliano T; Esposito S; Lusso P; Tambussi G; Malnati MS
    J Clin Virol; 2016 May; 78():47-52. PubMed ID: 26985593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to liposomal doxorubicin and clinical outcome of HIV-1-infected patients with Kaposi's sarcoma receiving highly active antiretroviral therapy.
    Núñez M; Saballs P; Valencia ME; Santos J; Ferrer E; Santos I; Berrocal A; Galindo MJ; Podzamczer D; Gonzlez-Lahoz J;
    HIV Clin Trials; 2001; 2(5):429-37. PubMed ID: 11673818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.